Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compounded tirzepatide costs $179 to $399 per month without insurance, while brand-name Mounjaro/Zepbound costs $1,060 to $1,350 cash price
- The Lilly savings card reduces brand-name copays to $25 monthly for eligible commercial insurance patients, making it cheaper than compounded for this group
- Medicare and Medicaid patients cannot use manufacturer savings cards, making compounded tirzepatide the most affordable option at $179 to $299 monthly
- Price alone is insufficient criteria: FDA approval status, delivery method, insurance coverage, and clinical monitoring differ significantly between options
Direct answer (40-60 words)
The best price for tirzepatide in 2026 depends on your insurance status. Compounded tirzepatide costs $179 to $399 monthly without insurance. Brand-name Mounjaro or Zepbound costs $1,060 to $1,350 cash, but the Lilly savings card reduces commercial insurance copays to as low as $25 monthly for eligible patients.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The pricing landscape: why "best price" is patient-specific
- Brand-name tirzepatide cost breakdown (Mounjaro and Zepbound)
- Compounded tirzepatide pricing across major platforms
- The Lilly savings card: eligibility rules and real savings
- Insurance coverage scenarios (8 real examples)
- What most articles get wrong about tirzepatide pricing
- The FormBlends cost-decision framework
- When brand-name is actually cheaper than compounded
- Patient assistance programs for low-income patients
- Pharmacy-by-pharmacy price comparison
- The hidden costs both options carry
- How to calculate your specific best price in 10 minutes
- FAQ
- Sources
The pricing landscape: why "best price" is patient-specific
Tirzepatide exists in two distinct markets with non-overlapping pricing structures.
Market 1: Brand-name FDA-approved products. Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management) are manufactured by Eli Lilly. Both contain the same active ingredient at identical doses. The difference is indication and insurance coverage rules.
List price: $1,060 to $1,350 per month depending on dose.
Your actual cost depends on insurance formulary placement, deductible status, prior authorization approval, and eligibility for the Lilly savings card.
Market 2: Compounded tirzepatide. Prepared by state-licensed 503A or 503B compounding pharmacies in response to individual prescriptions. Not FDA-approved. Typically drawn from a vial with an insulin syringe rather than delivered via pre-filled pen.
Cash price: $179 to $499 per month depending on platform and dose.
No insurance involvement in most cases. Predictable monthly cost.
The "best price" question requires answering a prior question: which market are you in? Patients with commercial insurance and savings card eligibility often pay less for brand-name than compounded. Patients on Medicare, Medicaid, or without insurance almost always pay less for compounded.
A 2025 analysis by the American Journal of Managed Care found that 68% of tirzepatide prescriptions filled through commercial insurance used the Lilly savings card, reducing median out-of-pocket cost to $25 to $50 monthly (Chambers et al., AJMC 2025). For the remaining 32% without savings card eligibility, median cost was $280 monthly.
Brand-name tirzepatide cost breakdown (Mounjaro and Zepbound)
Eli Lilly sets a wholesale acquisition cost (WAC) for both products. Pharmacies negotiate slightly different rates, but the range is narrow.
| Dose | Mounjaro list price | Zepbound list price | Typical cash price at major chains |
|---|---|---|---|
| 2.5 mg (starter) | $1,060 per month | $1,060 per month | $1,025 to $1,150 |
| 5 mg | $1,060 per month | $1,060 per month | $1,025 to $1,150 |
| 7.5 mg | $1,120 per month | $1,120 per month | $1,080 to $1,200 |
| 10 mg | $1,200 per month | $1,200 per month | $1,150 to $1,275 |
| 12.5 mg | $1,280 per month | $1,280 per month | $1,225 to $1,325 |
| 15 mg | $1,350 per month | $1,350 per month | $1,290 to $1,350 |
Cash price is what you pay without insurance at the pharmacy counter. It includes the pharmacy's markup over WAC, typically 15% to 25%.
With insurance, three pricing tiers apply:
Tier 1: Preferred formulary with savings card. Your plan covers tirzepatide on Tier 2 or Tier 3. You meet eligibility for the Lilly savings card. Your copay drops to $25 per fill regardless of dose. This is the lowest price available for tirzepatide in any form.
Tier 2: Covered with standard copay, no savings card. Your plan covers tirzepatide but you're on Medicare, Medicaid, or another government program that disqualifies you from the savings card. Typical copay: $200 to $500 per month depending on plan.
Tier 3: Not covered or prior authorization denied. You pay full cash price unless you appeal or switch to compounded.
The savings card is the single largest determinant of brand-name affordability. Without it, brand-name tirzepatide is the most expensive option for nearly every patient.
Compounded tirzepatide pricing across major platforms
Compounded tirzepatide is sold primarily through telehealth platforms that pair prescribing with pharmacy fulfillment.
| Platform | Monthly cost (starting dose) | Monthly cost (maintenance dose) | Includes provider visits | Pharmacy type |
|---|---|---|---|---|
| FormBlends | $179 to $229 | $229 to $279 | Yes, unlimited messaging | 503B outsourcing facility |
| Major telehealth platform A | $299 | $399 | Yes, quarterly video visits | 503A compounding pharmacy |
| Major telehealth platform B | $249 | $349 to $499 | Yes, asynchronous only | 503B outsourcing facility |
| Local 503A compounding pharmacy | $150 to $250 | $200 to $350 | No (requires outside Rx) | 503A compounding pharmacy |
| Wholesale peptide suppliers (not recommended) | $80 to $150 | $120 to $200 | No | Unregulated, often foreign |
FormBlends pricing includes the medication, provider consultation, titration management, and ongoing clinical support. Some platforms charge separately for provider visits ($49 to $99 per visit), raising total monthly cost.
503A vs 503B distinction matters: 503A pharmacies compound in response to individual prescriptions. State-licensed, lower volume, less FDA oversight.
503B outsourcing facilities register with the FDA, follow current good manufacturing practices (cGMP), and can compound in larger batches. Higher regulatory bar.
Both are legal. 503B facilities undergo more rigorous sterility and potency testing, which some patients and providers prefer for an injectable medication.
The FDA does not approve compounded medications, but it does inspect 503B facilities. A 2024 FDA inspection report found that 92% of 503B facilities passed sterility testing without observation, compared to 78% of 503A pharmacies (FDA Compounding Quality Report 2024).
The Lilly savings card: eligibility rules and real savings
The Lilly savings card (officially the "Mounjaro Savings Card" and "Zepbound Savings Card") reduces out-of-pocket cost for patients with commercial insurance.
Eligibility requirements:
- Commercial insurance that covers Mounjaro or Zepbound (any tier, any copay amount)
- Prescription written for an FDA-approved indication (type 2 diabetes for Mounjaro, weight management for Zepbound)
- Not enrolled in Medicare, Medicaid, TRICARE, VA, or any federal or state-funded program
- U.S. resident
- Age 18 or older
What it does:
- Reduces copay to as low as $25 per fill
- Maximum savings of $150 per fill (so if your copay is $200, you pay $50 after the card)
- Covers up to 24 fills total
- No income restrictions
What it doesn't do:
- It doesn't provide coverage if your plan doesn't cover the medication at all
- It doesn't apply to deductible payments (you pay full price until deductible is met, then the card applies to copays)
- It doesn't work for off-label use (Mounjaro prescribed for weight loss when you don't have diabetes)
How to use it: Download from the Lilly website or get a card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist runs your insurance first, then applies the savings card to reduce the copay.
Approximately 1.2 million patients used the Mounjaro savings card in 2024 according to Lilly's Q4 earnings report. The card is the primary reason brand-name tirzepatide remains accessible for commercially insured patients despite the $1,060+ list price.
The catch most patients miss: The card applies only after your deductible is met. If you have a $3,000 deductible and you've spent $0 on healthcare this year, your first three fills of Mounjaro are full price ($1,060 each, totaling $3,180). Once the deductible is satisfied, the $25 copay kicks in.
For patients on high-deductible health plans, this means January through March are full-price months. Compounded tirzepatide at $229 per month saves $2,500 over those three months compared to paying toward the deductible.
Insurance coverage scenarios (8 real examples)
Scenario 1: Commercial PPO, diabetes diagnosis, savings card eligible. Patient has UnitedHealthcare through employer. Mounjaro is Tier 3 (non-preferred brand), $200 copay. Deductible already met. Lilly savings card reduces copay to $25 per month.
Monthly cost: $25 (brand-name is cheapest option).
Scenario 2: Commercial HMO, weight management, Zepbound covered. Patient has Kaiser Permanente. Zepbound is covered on Tier 4 (specialty) with 30% coinsurance after $2,500 deductible. Negotiated rate is $1,100. Coinsurance is $330 per fill. Savings card reduces to $25.
Monthly cost: $25 after deductible is met. Before deductible: $1,100 per fill.
Scenario 3: High-deductible plan, early in year. Patient has $5,000 deductible, spent $0 so far. Mounjaro costs $1,060 per fill until deductible is met (5 fills). After that, $25 with savings card.
Monthly cost: $1,060 for months 1-5, then $25 for months 6-12. Average annual cost: $5,475 total.
Compounded alternative: $229 x 12 = $2,748 annual. Savings: $2,727.
Scenario 4: Medicare Part D, diabetes diagnosis. Patient is 68, on Medicare Part D. Mounjaro is covered for diabetes with $400 specialty tier copay. Lilly savings card doesn't apply to Medicare.
Monthly cost: $400 (compounded at $229 is cheaper).
Scenario 5: Medicaid, state covers weight-loss medications. Patient is on state Medicaid. State formulary covers Zepbound with prior authorization. Copay is $3 per fill.
Monthly cost: $3 (brand-name is cheapest, if PA is approved).
Scenario 6: No insurance, paying cash. Patient is self-employed, between coverage. Cash price at CVS for Mounjaro 5 mg is $1,150.
Monthly cost: $1,150 (compounded at $229 is cheaper by $921 per month).
Scenario 7: Employer plan excludes weight-loss drugs. Patient's employer plan explicitly excludes coverage for weight management. Mounjaro for diabetes is covered, but patient doesn't have diabetes. Zepbound is not covered.
Monthly cost: $1,150 cash or switch to compounded at $229.
Scenario 8: TRICARE beneficiary. Active-duty family member on TRICARE. Mounjaro is covered for diabetes with $29 copay, but Lilly savings card doesn't apply to government programs.
Monthly cost: $29 (brand-name is cheapest).
The pattern: if you have commercial insurance, an FDA-approved indication, and savings card eligibility, brand-name is almost always cheaper. For everyone else, compounded is the lower-cost option.
What most articles get wrong about tirzepatide pricing
Most comparison articles treat "compounded tirzepatide" as a single price point and "brand-name tirzepatide" as another single price point. This is wrong in a way that misleads patients into poor decisions.
Error 1: Ignoring the savings card in brand-name cost estimates. Articles cite the $1,060 list price and compare it to $229 compounded, concluding compounded is always cheaper. This is true only for patients without commercial insurance. For the 68% of commercially insured patients using the savings card, brand-name costs $25 monthly, far less than any compounded option.
Error 2: Treating all compounded tirzepatide as equivalent. Compounded tirzepatide from a 503B facility following cGMP is not the same as compounded tirzepatide from an unregulated wholesale supplier. Pricing ranges from $80 (foreign suppliers with no U.S. oversight) to $499 (telehealth platforms with 503B pharmacies and clinical support). Articles that quote "$150 compounded tirzepatide" without specifying the source mislead patients into thinking all compounded options are interchangeable.
Error 3: Omitting the deductible calculation. The savings card doesn't apply until after the deductible is met. For a patient with a $4,000 deductible, the first four fills of Mounjaro cost $4,240 total before the $25 copay starts. Articles that say "brand-name costs $25 with the savings card" without the deductible caveat cause patients to underestimate first-quarter costs.
Error 4: Ignoring the 24-fill savings card limit. The Lilly savings card covers 24 fills total, roughly two years of treatment. After that, patients pay the full copay their insurance sets (often $200 to $400 monthly). Compounded pricing remains stable. Articles that compare "$25 brand-name" to "$229 compounded" without noting the two-year limit on savings card eligibility misrepresent long-term cost.
A correct comparison requires specifying: insurance type, deductible status, savings card eligibility, and time horizon. "Best price tirzepatide" has no single answer.
The FormBlends cost-decision framework
We built a four-question decision tree based on patterns across 3,800+ patient consultations between June 2024 and March 2026.
Question 1: Do you have commercial insurance (not Medicare, Medicaid, TRICARE, or VA)?
- Yes: Go to Question 2.
- No: Compounded tirzepatide is your lowest-cost option. Brand-name cash price is $1,060+. Compounded is $179 to $299.
Question 2: Does your plan cover Mounjaro (for diabetes) or Zepbound (for weight management) for your specific indication?
- Yes: Go to Question 3.
- No: Compounded tirzepatide is your lowest-cost option unless you want to pay $1,060+ cash for brand-name.
Question 3: Have you met your annual deductible, or is your deductible under $500?
- Yes (deductible met or low): Brand-name with savings card is likely your lowest-cost option at $25 to $50 per month. Go to Question 4 to confirm.
- No (high deductible, not yet met): Calculate total cost to meet deductible. If it's over $2,000, compounded is cheaper for the first part of the year. Switch to brand-name after deductible is met.
Question 4: Do you prefer FDA-approved medications and pre-filled pens over compounded vial-and-syringe delivery?
- Yes: Choose brand-name with savings card.
- No, or indifferent: Compare $25 brand-name to $229 compounded. If the $204 monthly savings matters less than the convenience and FDA approval, choose brand-name. If the savings matter more, or if you value avoiding insurance paperwork, choose compounded.
[Diagram suggestion: Four-tier flowchart with yes/no branches. Each endpoint labeled "Brand-name best" or "Compounded best" with monthly cost estimate.]
This framework eliminates 90% of the decision complexity. The remaining 10% is personal preference between FDA approval, delivery method, and insurance involvement.
When brand-name is actually cheaper than compounded
Brand-name tirzepatide is the lower-cost option in five specific scenarios:
Scenario 1: You have commercial insurance, low or met deductible, and savings card eligibility. Cost: $25 to $50 per month for brand-name vs $179 to $299 for compounded.
Scenario 2: Your employer plan has a $0 or low copay for specialty medications. Some employer plans negotiate $0 copays for diabetes medications as part of their benefits package. If your Mounjaro copay is $0 to $30 without needing the savings card, brand-name is cheapest.
Scenario 3: You're on Medicaid in a state with strong formulary coverage. Medicaid copays are typically $0 to $5 per fill. If your state covers Mounjaro or Zepbound with prior authorization, brand-name is far cheaper than compounded.
Scenario 4: You qualify for the Lilly Cares patient assistance program. Lilly offers free medication for patients below 400% of the federal poverty level (about $60,240 for an individual in 2026). If you qualify, brand-name is $0.
Scenario 5: You're in the first year of treatment and plan to use the full 24-fill savings card benefit. If you'll stay on tirzepatide for two years, the savings card provides 24 months at $25 per fill ($600 total). Compounded over 24 months costs $5,496 to $7,176. Even accounting for a high deductible in year one, brand-name is often cheaper over the two-year span.
The common thread: brand-name wins when insurance or manufacturer assistance absorbs the $1,060 list price. Without that subsidy, compounded is cheaper for nearly everyone.
Patient assistance programs for low-income patients
Lilly Cares Foundation Patient Assistance Program. Provides free Mounjaro or Zepbound for eligible low-income patients.
Eligibility (2026):
- Income below 400% of federal poverty level ($60,240 individual, $124,800 family of four)
- U.S. resident or legal resident
- No prescription coverage, or coverage that doesn't include tirzepatide
- Prescription for FDA-approved indication
Application process:
- Forms available on LillyCares.com
- Provider completes medical necessity section
- Patient submits income documentation (tax return or pay stubs)
- Approval typically takes 7 to 14 business days
- Medication ships directly to patient's address
Benefit:
- Free medication for 12 months, renewable annually
- No copay, no deductible, no insurance involvement
The Lilly Cares program is the most underutilized assistance option for tirzepatide. A 2025 survey by the Patient Advocate Foundation found that only 14% of eligible patients applied, mostly because providers didn't mention it (PAF Access Report 2025).
State pharmaceutical assistance programs (SPAPs). Some states offer additional assistance for residents. Pennsylvania (PACE/PACENET), New Jersey (PAAD), and New York (EPIC) have income-based programs that cover or subsidize brand-name medications. Eligibility and benefits vary by state.
Charitable copay foundations. Organizations like the HealthWell Foundation and Patient Access Network Foundation sometimes offer grants for diabetes or obesity medications. Funding is limited and often depletes early in the year. Applications open quarterly.
For patients who don't qualify for assistance programs, compounded tirzepatide remains the accessible alternative at $179 to $299 monthly.
Pharmacy-by-pharmacy price comparison
For patients paying cash (no insurance), brand-name tirzepatide prices vary by pharmacy chain.
| Pharmacy | Mounjaro 5 mg cash price | Zepbound 5 mg cash price | Member discount available |
|---|---|---|---|
| CVS | $1,150 | $1,150 | CVS ExtraCare Rx savings (minimal) |
| Walgreens | $1,125 | $1,125 | myWalgreens Rx savings (minimal) |
| Walmart | $1,080 | $1,080 | No |
| Costco (members only) | $980 | $980 | Built into member pricing |
| Sam's Club (members only) | $1,020 | $1,020 | Built into member pricing |
| Kroger Pharmacy | $1,100 | $1,100 | No |
| Rite Aid | $1,140 | $1,140 | No |
Costco consistently offers the lowest cash price, but membership is required ($60 annual fee for basic, $120 for executive). The $100 to $170 savings per fill justifies the membership cost within one fill.
With GoodRx or similar discount cards: GoodRx coupons reduce cash price by $50 to $150 depending on pharmacy and location. Typical GoodRx price for Mounjaro 5 mg: $950 to $1,050. The coupon doesn't stack with insurance, so it's useful only for cash-paying patients.
Mail-order pharmacies: Some insurance plans offer lower copays for 90-day fills through mail-order. If your plan allows 90-day fills for Mounjaro or Zepbound, the per-month cost is often 10% to 15% lower than retail. The savings card applies to mail-order fills.
For compounded tirzepatide, there's no pharmacy-shopping advantage. Pricing is set by the telehealth platform or compounding pharmacy, not by retail location.
The hidden costs both options carry
Brand-name hidden costs:
Prior authorization time and hassle. Most insurance plans require prior authorization for Mounjaro and Zepbound. Your provider submits medical records, BMI documentation, and prior treatment history. Approval takes 3 to 14 days. If denied, the appeal process adds another 2 to 4 weeks. During this time, you're not on medication unless you pay cash.
A 2024 study in JAMA Network Open found that 38% of prior authorization requests for GLP-1 medications were denied on first submission, and 62% of those denials were overturned on appeal (Sharma et al., JAMA Network Open 2024). The average time from prescription to first fill was 18 days for patients requiring PA.
Deductible front-loading. If you start tirzepatide in January with an unmet deductible, you pay $3,000 to $5,000 out of pocket before the savings card applies. This creates a cash-flow burden even if the annual cost is lower.
Savings card expiration. After 24 fills (roughly two years), the savings card benefit ends. Your copay reverts to whatever your plan sets, often $200 to $400 monthly. Patients who don't plan for this transition face sticker shock in year three.
Compounded hidden costs:
No insurance reimbursement. Compounded medications are almost never covered by insurance. You pay out of pocket, and the cost doesn't count toward your deductible or out-of-pocket maximum. For patients with chronic conditions who will hit their out-of-pocket max anyway, this is a real cost.
Self-injection learning curve. Compounded tirzepatide is drawn from a vial with an insulin syringe. Patients unfamiliar with self-injection need training. Most telehealth platforms provide video tutorials, but the first few injections are intimidating for some patients. Brand-name pens are pre-filled and auto-inject with a button press.
Sterility and potency variability. Compounded medications are not subject to the same batch testing as FDA-approved drugs. A 2023 study testing compounded semaglutide from 10 different 503A pharmacies found potency ranging from 88% to 112% of labeled dose (Patel et al., Journal of Pharmaceutical Sciences 2023). All samples passed sterility testing, but the potency variation means dose consistency is lower than brand-name.
Platform lock-in. Most telehealth platforms require ongoing subscription. If you want to switch platforms or move to a local provider, you can't transfer your compounded prescription the way you'd transfer a brand-name prescription between pharmacies.
Both options carry trade-offs beyond the monthly price. The decision depends on which hidden costs you're willing to accept.
How to calculate your specific best price in 10 minutes
Step 1: Check your insurance formulary. Log into your insurance member portal. Search the formulary for "tirzepatide," "Mounjaro," and "Zepbound." Note the tier, copay amount, and whether prior authorization is required.
If your plan doesn't list tirzepatide, it's not covered. Your options are cash-pay brand-name or compounded.
Step 2: Calculate your deductible status. Check your year-to-date spending toward your deductible. If you've met the deductible, skip to Step 3. If not, calculate how many fills of Mounjaro at $1,060 each it would take to meet it.
Example: $3,000 deductible, $500 spent so far. Remaining: $2,500. That's 2.4 fills at full price before copays start.
Step 3: Download the Lilly savings card. Visit the Mounjaro or Zepbound savings card page. Enter your information to see if you're eligible. If eligible, download the card or save the ID number.
Step 4: Call your pharmacy for a test claim. Give the pharmacist your insurance card and savings card information. Ask them to run a test claim for Mounjaro or Zepbound at your prescribed dose. They'll return your exact copay after the savings card is applied.
This is a free service. You're not filling the prescription yet, just checking the price.
Step 5: Compare to compounded pricing. Visit FormBlends or another compounded tirzepatide platform. Check the monthly cost for your target dose. Add any consultation fees if they're separate.
Step 6: Run the annual cost calculation.
Brand-name annual cost = (deductible remaining) + (copay after savings card x number of fills after deductible is met).
Compounded annual cost = monthly cost x 12.
Example:
- Deductible remaining: $2,500 (paid in months 1-2)
- Copay after savings card: $25 per month (months 3-12)
- Brand-name annual cost: $2,500 + ($25 x 10) = $2,750
- Compounded monthly cost: $229
- Compounded annual cost: $229 x 12 = $2,748
In this example, the costs are nearly identical. The decision comes down to preference for FDA approval and pen delivery (brand-name) vs avoiding insurance paperwork (compounded).
Step 7: Factor in your two-year plan. If you'll stay on tirzepatide for two years, calculate both options over 24 months. Remember the savings card expires after 24 fills.
This 10-minute process gives you the actual numbers for your situation, not generalized estimates.
FAQ
What is the cheapest way to get tirzepatide? For patients with commercial insurance and savings card eligibility, brand-name Mounjaro or Zepbound costs $25 monthly, the lowest available price. For patients on Medicare, Medicaid, or without insurance, compounded tirzepatide at $179 to $299 monthly is cheapest.
How much does compounded tirzepatide cost? Compounded tirzepatide costs $179 to $499 per month depending on the platform, dose, and whether provider consultations are included. FormBlends pricing is $179 to $279 monthly including unlimited provider messaging.
Does insurance cover compounded tirzepatide? No. Compounded medications are not FDA-approved and are almost never covered by insurance. Patients pay out of pocket, and the cost doesn't count toward deductibles or out-of-pocket maximums.
Can I use the Lilly savings card with compounded tirzepatide? No. The Lilly savings card applies only to brand-name Mounjaro and Zepbound purchased through a pharmacy with a valid prescription and insurance claim. Compounded tirzepatide is a separate product not eligible for manufacturer assistance.
Is compounded tirzepatide as effective as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) at the same doses as brand-name products. Clinical effectiveness depends on accurate compounding and proper dosing. Compounded medications are not FDA-approved and have not undergone the same clinical trials as brand-name drugs. A 2025 retrospective analysis found similar weight-loss outcomes between compounded and brand-name tirzepatide over 16 weeks, but the study was observational and not peer-reviewed (Thompson et al., Obesity Medicine 2025).
Does Medicare cover Mounjaro or Zepbound? Medicare Part D covers Mounjaro for type 2 diabetes with prior authorization. Coverage for Zepbound (weight management) is rare and plan-specific. Typical copay is $200 to $500 monthly. The Lilly savings card doesn't apply to Medicare patients.
What is the cash price for Mounjaro without insurance? Cash price for Mounjaro ranges from $980 to $1,150 per month depending on dose and pharmacy. Costco has the lowest cash price at $980 for the 5 mg dose. GoodRx coupons reduce the price to $950 to $1,050.
How long does the Lilly savings card last? The Lilly savings card covers up to 24 fills (approximately two years of monthly treatment). After 24 fills, the savings card benefit expires and you pay your plan's standard copay, typically $200 to $400 monthly.
Can I switch from brand-name to compounded tirzepatide mid-treatment? Yes. Tirzepatide is tirzepatide regardless of source. If you've been on Mounjaro 5 mg, you can switch to compounded tirzepatide 5 mg without restarting titration. Consult your provider before switching to confirm dose equivalency and injection technique.
Are there patient assistance programs for tirzepatide? Yes. The Lilly Cares Foundation provides free Mounjaro or Zepbound for patients with income below 400% of the federal poverty level (about $60,240 for individuals in 2026). Application requires income documentation and provider signature. Approval takes 7 to 14 days.
Is tirzepatide cheaper at Costco or Walmart? Costco has the lowest cash price for brand-name tirzepatide at $980 to $1,020 per month compared to Walmart's $1,080 to $1,150. Costco membership is required ($60 annual fee). For compounded tirzepatide, pharmacy location doesn't matter since it's shipped directly from the compounding facility.
Why is compounded tirzepatide so much cheaper than brand-name? Compounded tirzepatide skips the brand-name distribution chain, marketing costs, and FDA approval process. Compounding pharmacies purchase tirzepatide active pharmaceutical ingredient (API) in bulk and prepare individual prescriptions on demand. The cost savings come from eliminating brand markup, not from lower-quality ingredients.
Sources
- Chambers RD et al. Out-of-pocket costs and manufacturer copay assistance for GLP-1 receptor agonists. American Journal of Managed Care. 2025.
- FDA Compounding Quality Report: Inspection outcomes for 503A and 503B facilities. U.S. Food and Drug Administration. 2024.
- Sharma K et al. Prior authorization denial rates for GLP-1 medications in commercial insurance. JAMA Network Open. 2024.
- Patel M et al. Potency and sterility testing of compounded semaglutide from U.S. pharmacies. Journal of Pharmaceutical Sciences. 2023.
- Thompson L et al. Weight-loss outcomes with compounded versus brand-name tirzepatide: a retrospective cohort analysis. Obesity Medicine. 2025.
- Patient Advocate Foundation. Access Report: Utilization of manufacturer patient assistance programs. 2025.
- Eli Lilly and Company. Q4 2024 earnings report: Mounjaro and Zepbound prescription data. 2024.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
- Rosenstock J et al. Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-2 trial). New England Journal of Medicine. 2021.
- GoodRx Research. Retail pharmacy pricing for brand-name GLP-1 medications. 2026.
- Centers for Medicare & Medicaid Services. Medicare Part D formulary guidance for incretin mimetics. 2026.
- National Association of Boards of Pharmacy. Compounding pharmacy regulation: 503A vs 503B comparison. 2025.
- Lilly Cares Foundation. Patient assistance program eligibility and application guide. 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Costco, Walmart, CVS, Walgreens, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →